Neoleukin Therapeutics Valuation
| NLTXDelisted Stock | USD 0.69 0.01 1.43% |
Neoleukin Therapeutics is overvalued. Neoleukin Therapeutics secures a last-minute Real Value of $0.63 per share. The latest price of the firm is $0.69. Our model forecasts the value of Neoleukin Therapeutics from analyzing the firm fundamentals such as Current Valuation of (35.02 M), return on equity of -0.38, and Shares Owned By Insiders of 16.46 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Neoleukin Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Neoleukin Therapeutics is based on 3 months time horizon. Increasing Neoleukin Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Neoleukin Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neoleukin Stock. However, Neoleukin Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.69 | Real 0.63 | Hype 0.69 |
The intrinsic value of Neoleukin Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Neoleukin Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Neoleukin Therapeutics helps investors to forecast how Neoleukin stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neoleukin Therapeutics more accurately as focusing exclusively on Neoleukin Therapeutics' fundamentals will not take into account other important factors: Neoleukin Therapeutics Total Value Analysis
Neoleukin Therapeutics is now anticipated to have valuation of (35.02 M) with market capitalization of 8.2 M, debt of 12.07 M, and cash on hands of 116.46 M. The negative valuation of Neoleukin Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Neoleukin Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(35.02 M) | 8.2 M | 12.07 M | 116.46 M |
Neoleukin Therapeutics Asset Utilization
One of the ways to look at asset utilization of Neoleukin is to check how much profit was generated for every dollar of assets it reports. Neoleukin Therapeutics secures a negative usage of assets of -0.19 %, losing $0.001871 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Neoleukin Therapeutics shows how discouraging it operates for each dollar spent on its assets.Neoleukin Therapeutics Ownership Allocation
30% of Neoleukin Therapeutics outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.Neoleukin Therapeutics Profitability Analysis
Net Loss for the year was (57.56 M) with profit before overhead, payroll, taxes, and interest of 0.About Neoleukin Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Neoleukin Therapeutics. We calculate exposure to Neoleukin Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Neoleukin Therapeutics's related companies.Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Neoleukin Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.
Neoleukin Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 55.2 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Neoleukin Stock
If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |